The Canopy Cancer Collective Clinical Registry Protocol

Part of paid clinical trials in San Diego, California.

Sponsor
Canopy Cancer Collective, LLC
Study ID
NCT07605702
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol Number of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes. Secondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory. 2\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory. Research Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes. Drugs/Devices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and/or their affiliates Sample Size Up to 30000 patients in the prospective component Up to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
May 31, 2036
Completion
May 31, 2038

Study Design

Enrollment
100,000 participants (estimated)

Primary Outcome Measure

Number of participants enrolled in registry [ Time Frame: Up to 120 months ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
UC San Diego HealthSan DiegoCalifornia92093
Gregory Botta, MD
866-773-2703
Moffitt Cancer CenterTampaFlorida33612
Sarah Hoffe, MD
888-663-3488
Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287
Amol Narang, MD
410-502-8000
Roswell Park Comprehensive Cancer CenterBuffaloNew York14203
Christos Fountzilas, MD
716-845-2300
Northwell HealthLake SuccessNew York11042
Dan King, MD
516-734-8900
Mt. SinaiNew YorkNew York10029
Karyn Goodman
212-241-0385
Cleveland ClinicClevelandOhio44195
Chase Wehrle, MD
216-399-9665
UT Southwestern Medical CenterDallasTexas75390
Todd Aguilera, MD
214-645-5383
UT Health San AntonioSan AntonioTexas78229
Rich Tuli, MD
210-567-7000
Fred HutchSeattleWashington98109
Andrew Coveler, MD
206-606-7509

Find similar trials in San Diego, CA

Related Studies